Firmness perception influences women’s preferences for vaginal suppositories

Pharmaceutics

Volumn 6, Issue 3, 2014, Pages 512-529

  Zaveri, Toral ^a,b   Primrose, Rachel J ^a,b   Surapaneni, Lahari ^b   Ziegler, Gregory R ^b   Hayes, John E ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Acceptability; Microbicide; Product optimization; Semisoft suppository; Sensory perception; Tenofovir

Indexed keywords

ALPHA TOCOPHEROL; CARRAGEENAN; ETHINYLESTRADIOL PLUS ETONOGESTREL; MICONAZOLE; SPERMICIDAL AGENT; TENOFOVIR;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; ELASTICITY; EX VIVO STUDY; FEMALE; FILM; FIRMNESS; GEL; HUMAN; IN VITRO STUDY; MECHANICS; MENSTRUAL TAMPON; PATIENT PREFERENCE; PHYSICAL PARAMETERS; SIMULATION; SUPPOSITORY; VAGINA DISCHARGE; VAGINAL DOUCHE; YOUNG MODULUS;

EID: 84937045159     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6030512     Document Type: Article

References (40)

1. Abdool Karim, Q.; Abdool Karim, S.S.; Frohlich, J.A.; Grobler, A.C.; Baxter, C.; Mansoor, L.E.; Kharsany, A.B.M.; Sibeko, S.; Mlisana, K.P.; Omar, Z., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329, 1168–1174
2. Stone, A. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug. Discov. 2002, 1, 977–985
3. Schwartz, J.L.; Rountree, W.; Kashuba, A.D.M.; Brache, V.; Creinin, M.D.; Poindexter, A.; Kearney, B.P. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011, 6, e25974
4. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Available online: http://www.mtnstopshiv.org/node/3909 (accessed on 10 February 2014).
5. Van der Straten, A.; van Damme, L.; Haberer, J.E.; Bangsberg, D.R. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012, 26, F13–F19
6. Behavioral Measures of Product Use Didn’t Measure Up in VOICE HIV Prevention Trial, Report the Study’s Researchers. Available online: http://www.mtnstopshiv.org/node/5486 (accessed on 6 May 2014).
7. Carballo-Diéguez, A.; Giguere, R.; Dolezal, C.; Bauermeister, J.; Leu, C.-S.; Valladares, J.; Frasca, T.; Labbett, R.; Cranston, R.; Febo, I., et al. Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: Implications for microbicide research. AIDS Behav. 2014, 18, 1726–1733
8. Leu, C.-S.; Mabragaña, M.; Giguere, R.; Dolezal, C.; Carballo-Diéguez, A.; McGowan, I. Use of a novel technology to track adherence to product use in a microbicide trial of short duration (MTN-007). AIDS Behav. 2013, 17, 3101–3107
9. Hemmerling, A.; Harrison, W.G.; Brown, J.M.; Moscicki, B.; Oziemkowska, M.; Bukusi, E.A.; Cohen, C.R. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex. Transm. Dis. 2012, 39, 710–712
10. Bentley, M.E.; Fullem, A.M.; Tolley, E.E.; Kelly, C.W.; Jogelkar, N.; Srirak, N.; Mwafulirwa, L.; Khumalo-Sakutukwa, G.; Celentano, D.D. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 2004, 94, 1159–1164
11. Morrow, K.; Rosen, R.; Richter, L.; Emans, A.; Forbes, A.; Day, J.; Morar, N.; Maslankowski, L.; Profy, A.T.; Kelly, C., et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J. Womens Health 2003, 12, 655–666
12. Morrow, K.; Underhill, K.; Berg, J.; Vargas, S.; Rosen, R.; Katz, D. User-identified gel characteristics: A qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch. Sex. Behav. 2014, doi:10.1007/s10508-013-0235-5
13. Morrow, K.M.; Fava, J.L.; Rosen, R.K.; Vargas, S.; Shaw, J.G.; Kojic, E.M.; Kiser, P.F.; Friend, D.R.; Katz, D.F.; David, F. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: Relating user sensory perceptions and experiences to formulation properties. AIDS Res. Hum. Retroviruses 2014, 30, 78–91
14. Van den Berg, J.J.; Rosen, R.K.; Bregman, D.E.; Thompson, L.A.; Jensen, K.M.; Kiser, P.F.; Katz, D.F.; Buckheit, K.; Buckheit, R.W., Jr., et al. “Set it and forget it”: Women’s perceptions and opinions of long-acting topical vaginal gels. AIDS Behav. 2014, 18, 862–870
15. Zaveri, T.; Powell, K.A.; Li, B.; Ziegler, G.R.; Hayes, J.E. The society of sensory professionals 3rd technical and professional conference. In Proceedings of the Improving Acceptability of Vaginal Drug Delivery Systems by Using Sensory Methods, Jersey City, NJ, USA, 10–12 October 2012
16. Nel, A.M.; Mitchnick, L.B.; Risha, P.; Muungo, L.T.; Norick, P.M. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among african women. J. Womens Health 2011, 20, 1207–1214
17. Li, B.; Zaveri, T.; Ziegler, G.R.; Hayes, J.E. User preferences in a carrageenan-based vaginal drug delivery system. PLoS One 2013, 8, e54975
18. Pereira, L.E.; Clark, M.R.; Friend, D.R.; Garber, D.A.; McNicholl, J.M.; Hendry, R.M.; Doncel, G.F.; Smith, J.M. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob. Agents Chemother. 2014, 58, 2665–2674
19. Cole, A.M.; Patton, D.L.; Rohan, L.C.; Cole, A.L.; Cosgrove-Sweeney, Y.; Rogers, N.A.; Ratner, D.; Sassi, A.B.; Lackman-Smith, C.; Tarwater, P., et al. The formulated microbicide rc-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 2010, 5, e15111
20. Akil, A.; Parniak, M.A.; Dezzuitti, C.S.; Moncla, B.J.; Cost, M.R.; Li, M.; Rohan, L.C. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res. 2011, 1, 209–222
21. Forbes, C.J.; McCoy, C.F.; Murphy, D.J.; Woolfson, A.D.; Moore, J.P.; Evans, A.; Shattock, R.J.; Malcolm, R.K. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J. Pharm. Sci. 2014, 103, 1422–1432
22. Grammen, C.; Ariën, K.K.; Venkatraj, M.; Joossens, J.; van der Veken, P.; Heeres, J.; Lewi, P.J.; Haenen, S.; Augustyns, K.; Vanham, G., et al. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral. Res. 2014, 101, 113–121
23. Devlin, B.; Nuttall, J.; Wilder, S.; Woodsong, C.; Rosenberg, Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral. Res. 2013, 100, S3–S8
24. Fetherston, S.M.; Boyd, P.; McCoy, C.F.; McBride, M.C.; Edwards, K.-L.; Ampofo, S.; Malcolm, R.K. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm. Sci. 2013, 48, 406–415
25. Giguere, R.; Carballo-Dieguez, A.; Ventuneac, A.; Mabragana, M.; Dolezal, C.; Chen, B.A.; Kahn, J.A.; Zimet, G.D.; McGowan, I. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult. Health Sex. 2012, 14, 151–166
26. Zacharopoulos, V.R.; Phillips, D.M. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin. Diagn. Lab. Immunol. 1997, 4, 465–468
27. González, M.E.; Alarcón, B.; Carrasco, L. Polysaccharides as antiviral agents: Antiviral activity of carrageenan. Antimicrob. Agents Chemother. 1987, 31, 1388–1393
28. Buck, C.B.; Thompson, C.D.; Roberts, J.N.; Müller, M.; Lowy, D.R.; Schiller, J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2, e69
29. Li, B.; Zaveri, T.; Ziegler, G.R.; Hayes, J.E. Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral. Res. 2012, 97, 280–284
30. DeMars, L.L.; Ziegler, G.R. Texture and structure of gelatin/pectin-based gummy confections. Food Hydrocoll. 2001, 15, 643–653
31. Owen, D.H.; Katz, D.F. A vaginal fluid simulant. Contraception 1999, 59, 91–95
32. Godley, M.J. Quantitation of vaginal discharge in healthy volunteers. Br. J. Obstet. Gynaecol. 1985, 92, 739–742
33. Stone, A.; Gamble, C.J. The quantity of vaginal fluid. Am. J. Obstet. Gynecol. 1959, 78, 279–281
34. Wagner, G.; Levin, R.J. Electrolytes in vaginal fluid during the menstrual cycle of coitally active and inactive women. J. Reprod. Fertil. 1980, 60, 17–27
35. Lawless, H.T. Progress in Affective Testing Preference Choice and Hedonic Scaling. In Quantitative Sensory Analysis: Psychophysics, Models and Intelligent Design; Wiley: New York, NY, USA, 2013; pp. 185–187
36. Zaveri, T.; Hayes, J.E.; Ziegler, G.R. Release of tenofovir from carrageenan-based vaginal suppositories. Pharmaceutics 2014, 6, 366–377
37. Hayes, J.E.; DePasquale, D.A.; Moser, S.E. Asymmetric dominance as a potential source of bias in hedonic testing. Food Qual. Prefer. 2011, 22, 559–566
38. Hendrickx, M.; Vandenabeele, C.; Engels, C.; Tobback, P. Diffusion of glucose in carrageenan gels. J. Food Sci. 1986, 51, 1544–1546
39. Huggins, G.R.; Preti, G. Vaginal odors and secretions. Clin. Obstet. Gynecol. 1981, 24, 355–377
40. Piculell, L.; Nilsson, S.; Muhrbeck, P. Effects of small amounts of κ-carrageenan on the rheology of aqueous ι-carrageenan. Carbohyd. Polym. 1992, 18, 199–208.